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Abstract. An extrusion-based 3D printer was used to fabricate paracetamol tablets with
different geometries (mesh, ring and solid) from a single paste-based formulation formed
from standard pharmaceutical ingredients. The tablets demonstrate that tunable drug release
proﬁles can be achieved from this single formulation even with high drug loading (> 80% w/
w). The tablets were evaluated for drug release using a USP dissolution testing type I
apparatus. The tablets showed well-deﬁned release proﬁles (from immediate to sustained
release) controlled by their different geometries. The dissolution results showed dependency
of drug release on the surface area/volume (SA/V) ratio and the SA of the different tablets.
The tablets with larger SA/V ratios and SA had faster drug release. The 3D printed tablets
were also evaluated for physical and mechanical properties including tablet dimension, drug
content, weight variation and breaking force and were within acceptable range as deﬁned by
the international standards stated in the US Pharmacopoeia. X-ray powder diffraction,
differential scanning calorimetry and attenuated total reﬂectance Fourier transform infrared
spectroscopy were used to identify the physical form of the active and to assess possible drug-
excipient interactions. These data again showed that the tablets meet USP requirement.
These results clearly demonstrate the potential of 3D printing to create unique pharmaceu-
tical manufacturing, and potentially clinical, opportunities. The ability to use a single
unmodiﬁed formulation to achieve deﬁned release proﬁles could allow, for example,
relatively straightforward personalization of medicines for individuals with different
metabolism rates for certain drugs and hence could offer signiﬁcant development and clinical
opportunities.
KEY WORDS: 3D printing; paracetamol; sustained release; immediate release; personalised medicine;
geometry.
INTRODUCTION
Personalised medicine is deﬁned as a customization of
health care to individual patients through linking diagnostics
and treatments with genetic testing and emerging technolo-
gies such as proteomics and metabolomics analysis (1). The
main advantages of this approach are to increase the
effectiveness of the prescribed treatment regimen and to
minimise their adverse effects such as those linked to
overdosing of drugs with a narrow therapeutic index such as
digoxin and anti-clotting agents (2). In the context of solid
oral dosage forms, conventional large-scale tableting
manufacturing methods are clearly unsuited to personalised
medicine and, in addition, provide restrictions on the
complexity achievable in the dosage form in terms of, for
example, tablet geometry, drug dosage, distribution and
combinations. 3D printing offers the potential for the
manufacture of bespoke solid oral dosage forms. 3D printers
also offer the possibility of reducing the number of
manufacturing steps as currently used in traditional tablet
production process, such as powder milling, wet granulation,
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dry granulation, tablet compression and coating and the
potential for rapid formulation development with limited
quantities of active ingredients as available in early drug
development (3,4).
3D printing is hence a potentially signiﬁcant platform that
can produce viable solid dosage forms in complex geometries in
a programmed, controlled manner and with accurate drug
loading (5–8). Many believe that 3D printers could play an
important role in the development of personalised unit dose
medication for targeting the speciﬁc needs of individual patients
and treatments (5,6,9). In envisaging how such an approach
could be taken to the practical manufacture of dosage forms, it
would clearly simplify matters greatly if the formulation (or ‘ink’
in 3D printer terms) could be kept as simple as possible, with
little need for the use of multiple formulations that must be
mixed precisely in situ within the 3D printer. Such a complex
mixing approach would greatly complicate supply chains,
increase quality control difﬁculties and subsequently raise
regulatory barriers even higher than might be expected for such
a new approach to manufacture. We propose, and demonstrate
here, that the required need for personalization in terms of drug
release proﬁle can be achieved by the control of tablet geometry
alone from a single formulation. Such an approach we propose
would signiﬁcantly increase the likelihood of 3D printing being
adopted for the development and manufacture of personalised
dosage forms.
Paracetamol is commercially available in many different
dosage forms including tablets, capsules, suspensions, suppos-
itories and intravenous solutions and is commonly used to
treat mild to moderate pain caused by headaches, toothache,
sprain or strains (4). Here, paracetamol was chosen as a well-
known freely available drug suitable for a proof of concept
study. The common paracetamol doses available range from
300 to 500 mg, although 1000 mg is also available in some
regions. Therefore, customising of paracetamol effect/release
(plasma peak levels) while prolonging its action by using
different tablet geometries is potentially desirable (10). The
effect of dosage form geometry on drug release for controlled
release has been reported (10–12). Previously, work has also
been done on 3D printing of paracetamol formulations
primarily using fused deposition modelling (FDM) 3D
printing (4,13–18). However, the high extrusion temperature
used in FDM (≥ 120°C) narrows the potential active ingredi-
ent library to include only heat stable actives (4). Other
possible 3D printing methods like stereolithography (SLA)
and ink-jet printing currently use excipients that are not
generally recognised as safe (GRAS) (13).
Different types of 3D printer are commercially available
including the aforementioned FDM, inkjet, selective laser
sintering (SLS) and SLA, and signiﬁcant work has been done
in the area of drug delivery using these approaches (7,12–
14,19–23). Published research regarding 3D printing tech-
niques to achieve controlled drug release include Sadia and
co-workers, who created multi-channelled tablets using FDM
for a Biopharmaceutics Classiﬁcation System (BCS) class IV
drug, hydrochlorothiazide (24). Also Yang et al. used FDM to
print tablets with differing internal scaffold structures to
control ibuprofen release (25). SLS has been used by Fina
et al. to create orally disintegrating paracetamol tablets whose
drug release depending upon the printing speed (17). We
have also previously demonstrated the ﬂexibility afforded by
3D extruding semi-solid formulations at ambient conditions
using compendia grades available to form tablets to achieve
controlled drug release (5,6,26). Whilst extrusion-based 3D
printing avoids the heat stress associated with other tech-
niques, it has some disadvantages including relatively low
spatial resolution compared to other 3D printing approaches,
and that it may not be suitable for water-sensitive materials
(degradation unless solvent or binder other than water is
used). In this research, the drying temperature was set at
80°C to accelerate the drying time of the printed tablets (4).
However, lower temperatures in a range of 40–60°C can be
employed, as is commonly used in drying oral solid dosage
form but this leads to longer drying times. The aim of this
work is to introduce extrusion-based 3D printer for the ﬁrst
time as a capable tool to print different geometries with




Paracetamol and polyvinylpyrrolidine (PVP K25) were
supp l i ed by S igma–Aldr i ch (Gi l l ingham, UK) .
Croscarmellose sodium (NaCCS) (Primellose®) was kindly
supplied as a gift from DFE Pharma. Starch was kindly
supplied by Colorcon®. Milli-Q water (resistivity
18.2 MΩ cm) was used for all formulations and solutions.
All other reagents were of either HPLC or analytical grade.
Methods
Design of Paracetamol Tablets
A strategy of controlling the geometry to be generally
oval shaped (easy to swallow) for the 3D printed tablets was
chosen (Fig. 1). A normal solid tablet geometry was altered to
also produce an oval ring and an oval tablet with an internal
mesh or lattice-like structure. The mesh tablets which were
printed in 13 layers in an external oval ring (formed from two
or three printed ovals) and an internal cross-lattice mesh
format. There was an internal gap of 0.4 mm between the two
printed oval walls of layers 2–12 (Fig. 1), with the top (layer
13) and bottom (layer 1) layers having three oval walls
printed around the mesh structure with no gap between them
to ensure tablet integrity. The ring tablets were simply
produced by printing oval walls of different dimensions until
the ring-like structure was achieved. The outer dimensions of
the designed oval tablets were 15 mm length × 8 mm width ×
3.2 mm height for the solid tablets, 4.8 mm height for the ring
tablets and 5.2 mm height for the mesh tablets. The geometry
of the tablets was designed using a 3D drawing package
(BioCAD, regenHU Villaz-St-Pierre, Switzerland) with the
aim of keeping the tablet weight constant across the three
geometries.
3D Printing Process of Paracetamol Tablets
Twelve grams of ground paracetamol and the required
excipient powders (starch, PVP K25 and NaCCS) were mixed
using a mortar and pestle for 10 min. Milli-Q water (4.5 ml)
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(resistivity 18.2 MΩ cm) was added, and the powder was
mixed to form a paste according to the formulae shown in
Table I.
Extrusion-Based 3D Printing Process
A plastic 20 cm3 syringe (Optimum® syringe barrels,
Nordson EFD) was used to ﬁll the paste into the syringe
cartridge in the 3D printer (regenHU 3D). A stopper was ﬁxed
into Luer-Lock thread at the top end of the barrel after the
ﬁlling process to avoid any unintentional leakage of paste from
the cartridge showed in Fig. 2. Once ready for printing, the
stopper was removed, and the required nozzle (Optimum®
SmoothFlow™ tapered dispensing tips, 0.6 mm internal diam-
eter (ID) Nordson EFD) installed. The ﬁlled cartridge was then
installed into the printer head, and the paste was extruded layer
by layer until the desired tablet dimension was reached (Fig. 2).
The 3D printed tablets were left on a heated printing platform
(80°C) overnight for complete drying. The tablets were stored in
a sealed desiccator stored in a cool and dry location. The
following printing parameters were used: tip diameter 0.6 mm,
printing speed = 6 mm/s, printing pressure = 1.8 bar, number of
printed layers = 13 for mesh tablets, 12 for ring tablets and 8 for
solid tablets. The tablet outer dimensions were kept the same,
but the geometries were varied using functions in BioCAD
software. The tablet weights were kept constant within a
measured range of 308.01 ± 4.52 mg by adjusting the printed
tablet height.
Dissolution Studies
In vitro drug release studies of the paracetamol 3D
printed tablets were performed using a USP Type I apparatus
(rotation speed at 30 rpm, 900 ml phosphate buffer, pH 6.8 as
the dissolution media at 37 ± 0.5°C). Samples (5.0 ml) were
withdrawn at 5, 10, 15, 30, 60, 120, 240, 360, 480, 600 and
720 min. The samples were centrifuged and 0.5 ml from the
supernatant was drawn and diluted to 10 ml using the
dissolution medium. The samples were analysed with a UV–
vis spectrophotometer (Cary® 50 UV-vis spectrophotometer)
at a λ max of 243 nm. Drug dissolution studies were
conducted in sextuplicate, and the average of percentage of
cumulative drug release as a function of time was determined.
Although the USP monograph speciﬁcations for paracetamol
Fig. 1. Schematic structural diagram of paracetamol 3D printed tablets with different geometric shapes; mesh, ring and solid tablets
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tablet dissolution testing state that the dissolution rotation
should be 50 rpm, a speed of 30 rpm was chosen to ensure
that the tablet disintegration occurred mainly due to the
effect of disintegrants rather than effects caused by basket
rotation.
Characterisation Techniques
X-Ray Powder Diffraction (XRPD)
The XRPD patterns of pure paracetamol, excipients
(PVP K25, NaCCS and starch) and paracetamol formulation
powder (powder mixture after tablet ground into powder)
were obtained at room temperature using an X’Pert PRO
(PANalytical, Almelo, Netherlands) setup in reﬂection mode
using Cu Kα1 (lambda = 1.54 Å) operating in Bragg–
Brentano geometry. The generator voltage was set to 40 kV
and the current to 40 mA, and the samples were scanned over
2θ range of 5° until 30° in a step size of 0.026°.
Attenuated Total Reflectance Fourier Transform Infrared
Spectroscopy (ATR-FTIR)
Infrared spectra of pure paracetamol, excipients powders
(PVP K25, NaCCS and starch) and paracetamol formulation
powder (powder mixture after tablet ground into powder)
were obtained using an ATR-FTIR (Agilent Cary 630 FTIR)
spectrometer.
Differential Scanning Calorimetry (DSC)
The DSC measurements were performed on a TA
Instruments’ DSC Q2000 coupled to Universal Analysis
2000 with a thermal analyser. DSC analysis on such drug-
excipient mixtures were obtained by grinding paracetamol
tablets and sieving the powders (< 150 μm). Accurately
weighed samples of 3–5 mg were placed and sealed in
aluminium pans. The scans were performed under nitrogen
ﬂow (50 mL/min) at a heating rate of 10°C/min from 35 to
200°C. An empty sealed aluminium pan was used as a
reference.
Physical Properties of Paracetamol Immediate Release 3D
Printed Tablets
Dimension of Paracetamol 3D Printed Tablets
To conﬁrm the tablet size reproducibility, six tablets from
each geometry were measured using Vernier callipers and
their average values calculated.
Table I. The Percentage Composition of Various Ingredients in Paracetamol Formulation Feedstock






Paracetamol API 810.42 58.94 81.04 249.42
PVP Binder 100.00 7.27 10.00 30.78
Starch Binder 83.33 6.06 8.33 25.64
CCS Disintegrant 6.25 0.45 0.63 1.94
Water Binder 375.00 27.27 – –
Total – 1375.00 100.00 100.00 307.78
API active pharmaceutical ingredient, PVP polyvinylpyrrolidone, CCS croscarmellose sodium
aCalculated from the average of the total paracetamol tablet weight (307.78 mg, n = 6)
Fig. 2. Schematic diagram of cartridge/barrel tool ﬁlling process
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Weight Variation and Drug Content in the Final Tablet
Six paracetamol 3D printed tablets (from each geometry)
were individually weighed and their average weight calculated.
The individual tablet total weight deviation (%) was calculated.
Paracetamol content in the ﬁnal tablet was measured as follows:
from each batch, 10 paracetamol tablets were weighed and
crushed into powder. A quantity of paracetamol formulation
powder equivalent to 0.25 g of paracetamol was weighed and
transferred into a 1000 ml volumetric ﬂask. Nine hundred
millilitres of dissolution medium was added to the ﬂask and
placed on a stirrer for 4 h. Samples (5.0 ml) were withdrawn and
centrifuged. From the supernatant, 0.5ml was drawn and diluted
to 10 ml using the dissolution medium. The samples were
analysed with a UV–vis spectrophotometer (Cary® 50 UV-vis
spectrophotometer) at a λ max of 243 nm. Content uniformity
studies were conducted in triplicate, and the average of
percentage of paracetamol content was determined.
Breaking Force
Six paracetamol 3D printed tablets (from each geometry)
were randomly selected and tested for breaking force using a
hardness tester (Hardness tester C50, I Holland Ltd.,
Holland). The breaking force values were recorded in N
(Newton) units, and the tensile strength values were calcu-
lated using Eq. 1 (27,28). The tablet breaking force test was
done parallel to the longest axis of the paracetamol tablets.
σ f ¼ 3FL=2bd2 ð1Þ
where σf is the tensile fracture strength of the tablet, F is the
breaking force, L is the tablet length, b is the tablet width and
d is the tablet thickness.
Friability
Ten paracetamol 3D printed tablets (from each geome-
try) were selected randomly, and the tablets were accurately
weighed (initial weight). The tablets were placed in a friability
tester and rotated at a constant speed of 25 rpm for a period
of 4 min in Erweka friabilator. The tablets were cleaned of
any loose dust and reweighed (ﬁnal weight), and the weight
loss % (friability) was calculated.
RESULTS AND DISCUSSION
Tablet Printing
Batches of tablets were printed following the method
outlined in Fig. 2. Examples of printed tablets are shown in Fig. 3.
Fig. 3. The regenHU 3D printer (left) and image of paracetamol tablets 15.35 mm length × 8.41 mm width × 3.44 mm height for solid tablets,
15.24 mm length × 8.41 mm width × 4.8 mm height for ring tablets, and 15.22 mm length × 8.48 mm width × 5.46 mm height for mesh tablets
(average, n = 6) (right)
Fig. 4. In vitro cumulative paracetamol release proﬁles from three
different geometries; mesh, ring and solid paracetamol tablets, n = 6
(the printed tablets have different height but similar dimension and
total weight and dose)
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In vitro Drug Dissolution
Dissolution data from the paracetamol tablets (Fig. 4)
showed that the different tablet geometries with different
height but similar dimension and total weight and dose
(Tables IV and V) gave distinct release proﬁles. For the
paracetamol mesh tablets, more than 70% of the drug was
released within the ﬁrst 15 min. In contrast, only 25 and
12% of the drug was released in the same period from
the ring and the solid paracetamol tablets, respectively.
This indicates that the tablet surface area showed an
inﬂuence on drug release. Apart from surface area
exposed to solution, the drug release is also impacted by
the inclusion of the disintegrant, NaCCS, which rapidly
absorbs water and swells leading to rapid disintegration.
For the mesh tablets with the increased surface means
that water absorption takes place more rapidly than for
the ring and solid tablets (Fig. 4).
The drug release from the 3D printed tablets correlates
with the SA/V ratios, the higher the SA/V ratio value, the faster
the drug release (Table II). This trend has also been reported by
other researches (10,11,29). Goyanes et al. showed the effects of
SA/Vratios of different geometries on paracetamol release from
tablets prepared by hot melt extrusion (HME) (11). Also in the
same study, the authors showed that the drug release was
independent of the surface area (11). Research done by Yi et al.
demonstrated that the drug release from polylactic-co-glycolic
acid/polycaprolactone/5-ﬂuorouracil (PLGA/PCL/5-FU)
patches was dependent on the changes of SA produced by
geometric modiﬁcations (12). The authors then concluded that
the tendency of slowing drug release corresponded to a decrease
in the SA/V ratio (12). Furthermore, Gökçe et al. studied the
inﬂuence of tablet SA/V ratio of two different geometries
(cylinder and hexagonal) of the lipophilic matrix tablets of
metronidazole prepared by Cutina HR (hydrogenated castor
oil) (10). They found that the tablets with the highest release
rates for both geometric shapes reﬂecting the highest surface
area and the lowest SA/V ratio (10). Kyobula et al. showed that
hot melt 3D inkjet printing can be used to manufacture complex
and variable honeycomb geometry tablets for the controlled
loading and release of the drug fenoﬁbrate. In this case, the
surface area and wettability of the tablet were shown to
inﬂuence to the observed sustained drug release proﬁles (5).
Hence, as can reasonably be expected, we can conclude that the
tablet geometry and surface area generally have an effect on
drug release behaviour and are parameters that can be
manipulated to control drug release, even in formulations with
additives such as a swellable disintegrant, as here. The higher
the SA and SA/V ratio values, the faster the drug release is from
the 3D printed tablets (Fig. 4 and Table II).
The demonstrated ability to use a single unmodiﬁed
formulation to achieve deﬁned release proﬁles presents
opportunities to optimise or personalise medicines during
formulation development and in clinical use. For example,
relatively straightforward personalization of medicines
would be possible for individuals with different
metabolism rates due to their genetic makeup (26) for
certain drugs and hence could address issues where people
who metabolise drugs slowly may accumulate a toxic level
of a drug in the body or in others who process a drug
quickly and never have high enough drug concentrations
to be effective.
Drug Release Kinetics
To further understand the drug release mechanisms
displayed by the different geometries, the modes of release
of paracetamol over 12 h at a buffer pH 6.8 was modelled
using zero-order, ﬁrst-order, Higuchi and Korsmeyer–Peppas
models (30,31). According to ﬁtted r2 values, the mesh and
ring tablets were best ﬁtted by the ﬁrst-order equation (i.e.
log cumulative percentage of drug remaining is proportional
to the time) (32) and the solid tablets were best ﬁtted by the
Higuchi model (i.e. cumulative percentage drug release
versus square root of time) (32) with r2 values of 0.77, 0.97
and 0.99, respectively (Table III). The equation reveals n




Volume (V) (mm2) SA/V ratio Weight (mg) Tablet dimension (mm) Density (mg/mm3)
L ×H ×D
Mesh 897 ± 9.4 301 ± 3.9 2.976 ± 0.008 318 ± 11.1 15.2 ± 0.02 × 5.4 ± 0.05 × 8.5 ± 0.05 1.054 ± 0.023
Ring 449.94 ± 2.65 369.96 ± 3.25 1.216 ± 0.004 323.00 ± 1.70 15.3 ± 0.03 × 5.0 ± 0.06 × 8.5 ± 0.04 0.866 ± 0.005
Solid 330.94 ± 2.04 344.19 ± 5.19 0.962 ± 0.009 313.00 ± 9.20 15.4 ± 0.03 × 3.4 ± 0.06 × 8.4 ± 0.05 0.909 ± 0.013
L length, H height, D diameter
Table III. Fitting Experimental Release Data, from the In Vitro Release of 3D Printed Paracetamol Tablets to Zero-order, First-order, Higuchi
and Korsmeyer-Peppas Kinetic Equations at a Buffer Condition (pH 6.8–12 h)
Geometry Zero order (r2) First order (r2) Higuchi (r2) Korsmeyer-Peppas (r2) n value
Mesh 0.38 0.77 0.53 0.64 0.25
Ring 0.67 0.96 0.84 0.91 0.44
Solid 0.91 0.98 0.99 0.98 0.56
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values (as in Eq. (2)) of 0.25 for mesh tablets, 0.44 for ring
tablets and 0.56 for solid tablets.
Mt=M∞ ¼ Ktn ð2Þ
where Mt /M∞ is the fraction of drug released at time t, K is
the release rate constant and the release exponent (32,33).
The above results suggest that the drug is released
primarily by Fickian diffusion through a gel layer formed by
the amylose in the added starch. Amylose is known to absorb
water, swell and then form a gel layer (34). The drug release
from the mesh tablets was faster than the drug release from the
other geometries (ring and solid). This is, we propose, related to
the larger surface area (mesh>ring>solid) and the more easily
disrupted geometry of the mesh tablets where the chance to
form a stable gel layer, and hence, retard drug release is
inhibited. The disintegrants (the amylopectin (insoluble com-
ponent found in the starch that can absorb water, swell and act
as disintegrant) and NaCCS)) work to weaken and disrupt the
formed gel layer in the mesh tablets. In case of ring and solid
tablets, the geometry is more compact with a smaller surface
area and less exposure to the dissolution medium than mesh
tablets, so the disintegration rate is reduced, and there is an
increased time to form a gel layer and hence retardation of drug
release (solid>ring>mesh).
XRPD
XRPD of the pure paracetamol, excipients (PVP K25,
NaCCS and starch) and paracetamol formulation powder
(powder mixture after tablet ground into powder) was done
to investigate any potential changes in physical form of the
active on printing (Figs. 5 and 6). The Bragg peaks observed
from the pure paracetamol (as received) match the Bragg
peaks of paracetamol (calculated) reported in the Cambridge
Structural Database (CSD) (Fig. 5).
The results in Fig. 6 show that the paracetamol (non-
ground and ground powder) exhibited multiple sharp Bragg
peaks in their XRPD patterns related to their crystalline nature.
The post-printing XRPD data show the same Bragg peaks for
the paracetamol. There was, therefore, no evidence of a change
in physical form (form I) for the paracetamol in this formulation
fabricated using extrusion-based 3D printing. We believe that a
portion of the paracetamol powder could have dissolved after
addition a signiﬁcant quantity of water (4.5 ml) into total
paracetamol dry formulae (12 g) (paracetamol solubility
12.78 g/l /20°C) (34) as the whole mixture formed a paste;
however, this must have recrystallised back into form I if this
had occurred. The XRPD data from Fig. 6 also did not show
evidence of incompatibility between the active and the chosen
additives (PVPK25 (10%w/w), starch (8.33%w/w) andNaCCS
(0.63% w/w)) in the 3D printed tablets.
ATR-FTIR
Infrared spectral data show that the characteristic peak
positions remained unchanged from the paracetamol powder
to the formulation, indicating that there were no detectable
Fig. 5. XRPDpatterns of the calculated (top) and reference (measured)
paracetamol
Fig. 6. XRPD patterns of paracetamol powder (non-ground and ground form I) (left), paracetamol powder (ground form I), paracetamol
formulation, starch, PVP K25, NaCCS and brass (sample holder) (right)
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interactions between paracetamol (81% w/w) and the chosen
excipients (PVP K25 (10% w/w), starch (8.33% w/w) and
NaCCS (0.63% w/w)) in the tablets (Fig. 7).
DSC
DSC analysis was performed to explore potential incom-
patibility between the active and added excipients and the
stability of drug crystallinity after the 3D printing process
(grinding, mixing, paste formulation and drying process on a
hot plate heated at 80°C). The DSC data from Fig. 8 shows
that the pure powder of paracetamol melts at 169.7°C
conﬁrming the presence of form I (4,35,36) while the pure
powder of PVP K25 shows a glass transition (Tg) around
155°C (4,37). The same ﬁgure also shows clear evidence of an
endothermal event (melting point) at 169.24°C from the
printed paracetamol formulation, indicating that the active is
still in a crystalline form, speciﬁcally form I. From the above
results and discussions, we found that DSC thermogram of
paracetamol formulation powder after grinding, blending,
printing and post-printing processes with the excipients;
starch, PVP K25 and NaCCS did not show signiﬁcant changes
in peak placement apart from the peak depression and
reduction caused by the presence of the polymer in the
formulation in comparison to the peak obtained from the
pure paracetamol powder and again suggesting compatibility
of the excipients.
Physical Properties
The 3D printed tablets were evaluated for weight
variation, content uniformity, breaking force, friability and
tablet dimensions.
Tablet’s Shape and Dimension
Table IV conﬁrms that the tablet dimensions were
reproducible and comparable with the designed tablet’s size
and dimension and with the tablet size reported in the
literature prepared by conventional tableting press machines
(38–40).
Weight Variation
The paracetamol 3D printed tablets showed an accept-
able percentage weight variation (Table V) and, therefore,
comply with the USP speciﬁcation for uncoated tablets (±
7.5% for average weight of tablets 130–324 mg) (41,42). The
paracetamol content in the ﬁnal tablets was also assessed and
found to be 103.2 ± 1.1% for the mesh tablets, 104.0 ± 1.1%
for the ring tablets and 103.1 ± 1.5% for the solid tablets.
Fig. 7. FTIR spectra of paracetamol powder (ground form I) and paracetamol formulation (left), starch, PVP K25, NaCCS (right)
Fig. 8. DSC thermograms of pure paracetamol, paracetamol formu-
lation, starch, PVP K25 and NaCCS
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Breaking Force
Table VI shows the 3D printed tablets breaking forces
(kg and N) and the tensile fracture strength. Tensile fracture
strength of the paracetamol ﬂat-faced oval tablets was
calculated (28). In a conventional tableting press, compres-
sion forces can be used to control the physical properties of
the ﬁnal tablet, where a breaking force value of 4 kg is the
minimum satisfactory measurement (26,43). Measured break-
ing force measurements were within the accepted range of
8.69–9.56 kg for the solid tablets but failed to reach the
minimum satisfactory value for the mesh and ring tablets
(Table VI). It is clear that as compression force is not part of
3D printing process that the same opportunity to manipulate
tablet hardness in this way does not exist and rather the
formulation composition, solidiﬁcation/drying process and the
type of printer employed are critical factors. Clearly, further
work beyond the scope of this paper is required in this area;
however, from a subjective and qualitative assessment, the
ring and mesh paracetamol 3D printed tablets appear to be
quite robust and are able to tolerate a reasonable amount of
rough handling. For example, they could be dropped onto a
hard surface from a height of around 15 cm without
observable damage. In addition, such tablets could be
considered for manufacture close to the patient where
traditional wear factors such as chipping, capping and
abrasion which normally occurred during manufacturing,
packaging and shipping processes are not relevant.
Friability
This is a USP test used to determine a tablet resistance to
abrasion, capping and chipping occurred during manufacturing,
packaging and shipping processes. All paracetamol 3D printed
tablets of different geometries showed a satisfactory percentage
of weight loss ≤ 1% of the tablet weight (Table VII) and,
therefore, the tablets meet USP speciﬁcations (44).
Table IV. Individual Paracetamol 3D Printed Tablet’s Dimensions and Their Average, Median, Maximum, Minimum Dimension and Standard
Deviation
Tablet no. Mesh tablets (mm) Ring tablets (mm) Solid tablets (mm)
Length Height Width Length Height Width Length Height Width
1 15.24 5.42 8.50 15.01 5.13 8.30 15.39 3.50 8.35
2 15.21 5.51 8.47 15.33 5.08 8.47 15.40 3.46 8.47
3 15.20 5.40 8.38 15.38 4.94 8.50 15.34 3.36 8.46
4 15.22 5.46 8.51 15.30 5.07 8.40 15.36 3.52 8.33
5 15.26 5.45 8.53 15.26 5.09 8.42 15.26 3.38 8.42
6 15.19 5.49 8.47 15.16 5.06 8.38 15.37 3.42 8.45
Average 15.22 5.46 8.48 15.24 5.06 8.41 15.35 3.44 8.41
Median 15.22 5.46 8.49 15.28 5.08 8.41 15.37 3.44 8.44
Maximum 15.26 5.51 8.53 15.38 5.13 8.50 15.40 3.52 8.47
Minimum 15.19 5.40 8.38 15.01 4.94 8.30 15.26 3.36 8.33
SD 0.03 0.04 0.05 0.13 0.06 0.07 0.05 0.06 0.06
Table V. Individual Paracetamol 3D Printed Tablets Weight, Calculated Paracetamol Dose/Tablet, Percentage Deviation, and Their Average,
Median, Maximum, Minimum Weight and Standard deviation















1 312.90 253.57 0.78 308.80 250.25 0.33 307.10 248.87 0.44
2 318.80 258.36 2.68 300.70 243.69 − 2.30 302.20 244.90 − 1.16
3 309.90 251.14 − 0.19 311.90 252.76 1.34 301.30 244.17 − 1.46
4 307.70 249.36 − 0.90 312.60 253.33 1.57 306.40 248.31 0.21
5 310.80 251.87 0.10 306.00 247.98 − 0.58 306.60 248.47 0.28
6 302.80 245.39 − 2.47 306.70 248.55 − 0.35 310.90 251.95 1.68
Average 310.48 251.62 0.00 307.78 249.43 0.00 305.75 247.78 0.00
Median 310.35 251.51 − 0.04 307.75 249.40 − 0.01 306.50 248.39 0.25
Maximum 318.80 258.36 2.68 312.60 253.33 1.57 310.90 251.95 1.68
Minimum 302.80 245.39 − 2.47 300.70 243.69 − 2.30 301.30 244.17 − 1.46
SD 5.33 4.32 1.72 4.38 3.55 1.42 3.52 2.85 1.15
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CONCLUSIONS
Extrusion-based 3D printing of different paracetamol
tablet geometries with a high drug loading (81% w/w) was
successfully demonstrated. The mesh-geometry 3D printed
tablets released more than 70% of the active within 15 min
achieving immediate release mesh shaped tablets. In contrast,
only 25 and 12% of the drug was released in the same period
from the ring and the solid paracetamol tablets, respectively,
effectively demonstrating sustained release. Drug release
from the tablets showed a clear dependency on the SA/V
ratio. XRPD, FTIR and DSC data show that the paracetamol
form was unaffected by the printing and that there were no
detectable interactions between the paracetamol and the
chosen excipients (starch, PVP K25 and NaCCS). The 3D
printed paracetamol tablets were also evaluated for weight
variation, drug content in the ﬁnal tablets, hardness, friability
and tablet dimensions and were within acceptable range as
deﬁned by the international standards stated in the USP. This
work again validates that the extrusion-based 3D printing
process is capable of producing viable tablets from materials
having compendia grades available for pharmaceutical appli-
cations. More importantly this work demonstrates for the ﬁrst
time the application of extrusion-based printing for tailoring
of drug release from a single formulation through control of only
tablet geometry the ﬁrst. We believe this is a signiﬁcant step
forward in the potential wider take up of 3D printing for the
manufacture of medicines, particular in the areas of clinical
development and personalised medicines. With this principal
demonstrated, it becomes possible to envisage control of drug
release and dose (through dosage form size) on an individual
basis using a 3D printer, without the need for forming complex
mixtures from different formulation ‘cartridges’. This would
greatly simplify potential supply chains of formulation inks and
the quality control of the printed product.
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